Bellicum reports OS rates from Phase I/II of adjunct T cell therapy BPX-501

Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) reported data from 38 pediatric patients with acute myelogenous leukemia (AML) and 59 patients with primary immunodeficiencies undergoing a haploidentical hematopoietic stem cell transplant (HSCT) in the Phase I/II BP-004 trial evaluating BPX-501 to enhance immune reconstitution. In AML patients, BPX-501 led to a relapse-free survival rate of 91.5% and an overall survival (OS) rate of 97.3% at a median follow-up of one year. In patients with primary immunodeficiencies, BPX-501 led to a disease-free survival (DFS) rate of 88.1% and an OS rate of 88.6% at a median follow-up of one year.

The open-label, European trial’s primary endpoint is event-free survival. Secondary endpoints include transplant-related mortality, resolution of graft-versus-host disease (GvHD), immune reconstitution and safety...